Reyon Pharmaceutical이연제약
102460 · KOSPI · ₩102460 · 이연제약
₩9,680▼ ₩40 (0.41%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 26.1% | 26.2% | 49.1% | 52.2% | 53.1% | 55.6% |
| Operating margin | −20.2% | −20.7% | 0.1% | 2.7% | 6.3% | 2.6% |
| Net margin | −23.9% | −20.3% | 2.8% | 2.4% | 4.8% | 3.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −1.7% | −1.6% | −1.8% | −1.9% | +7.9% | — |
| Operating income growth | +4.2% | −38,289.4% | −98.0% | −58.1% | +157.6% | — |
| Net income growth | −15.6% | −813.8% | +15.8% | −51.8% | +34.2% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −16.5% | −12.6% | 1.7% | 1.4% | 3.0% | 2.3% |
| Return on assets | −5.1% | −6.1% | 0.8% | 0.7% | 1.5% | 1.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 128.0% | 111.1% | 100.0% | 101.0% | 95.6% | 94.9% |
| Net debt to equity | 42.3% | 41.9% | 31.6% | 30.8% | 2.6% | −18.0% |
| Current ratio | 49.6% | 55.6% | 66.0% | 79.5% | 227.3% | 346.9% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Reyon Pharmaceutical / 이연제약 / 102460 / KRX:102460
Source: KRX statistical information